Maze Therapeutics reports its latest quarterly results after market close today, with the stock up nearly 15% over the past week to $34.91, pulling away from most of its closest peers and cutting the gap to analyst targets that still sit well above the current price. Short interest in MAZE is a genuine part of the story here. At 15.3% of the free float, with roughly 7.35 million…
MAZE short interest surges 26.5% in one week to 9.1% of float, signaling mounting bearish positioning ahead of earnings Thursday.
Key data as of 10 Nov 2026
Maze Therapeutics reports Q1 2026 results on May 14 with short sellers freshly emboldened — and analysts split on how far the MZE829 story can run. The most striking pre-print development is in short positioning. Short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for MAZE — free to start on ORTEX.
Sign up for free →Open MAZE on ORTEX